A meta-analysis of 110 studies including randomized trials, prospective, and retrospective studies revealed that PD-1/PD-L1 inhibitors, particularly nivolumab, and pembrolizumab which are both categorized under PD-1, are associated with a high incidence of thyroid dysfunction, especially hypothyroidism[12]. This evidence concerns the gene PDCD1 and hypothyroidism.